Publications by authors named "D Yadin"
Immunoglobulins (Ig), which exist either as B-cell receptors (BCR) on the surface of B cells or as antibodies when secreted, play a key role in the recognition and response to antigenic threats. The capability to jointly characterize the BCR and antibody repertoire is crucial for understanding human adaptive immunity. From peripheral blood, bulk BCR sequencing (bulkBCR-seq) currently provides the highest sampling depth, single-cell BCR sequencing (scBCR-seq) allows for paired chain characterization, and antibody peptide sequencing by tandem mass spectrometry (Ab-seq) provides information on the composition of secreted antibodies in the serum.
View Article and Find Full Text PDFArticle Synopsis
- Danon disease is a rare genetic disorder caused by LAMP2 mutations, primarily affecting heart function, leading to significant morbidity and mortality.
- In mouse models, treatment with RAAS inhibitors like Ramipril and Spironolactone showed effectiveness in reducing heart enlargement and improving function, while Angiotensin II worsened heart conditions.
- Gene therapy with AAV9-LAMP2 decreased harmful autophagosome buildup and oxidative stress, suggesting potential therapeutic options for managing Danon's cardiomyopathy in humans.
Incivility in online commenting sections can create a hostile environment and result in the silencing of vulnerable voices. Accordingly, content websites and social media platforms have an ethical responsibility-one that aligns with their strategic interests-to minimize users' exposure to uncivil content. To this end, platforms invest great effort and budget in automatic and manual filtering mechanisms.
View Article and Find Full Text PDFDanon disease is a lethal X-linked genetic syndrome resulting from radical mutations in the LAMP2 gene. LAMP2 protein deficiency results in defective lysosomal function, autophagy arrest and a multisystem disorder primarily involving the heart, skeletal muscle and the central nervous system. Cardiomyopathy is the main cause of morbidity and mortality.
View Article and Find Full Text PDFBackground: Improving cancer immunotherapy long-term clinical benefit is a major priority. It has become apparent that multiple axes of immune suppression restrain the capacity of T cells to provide anti-tumour activity including signalling through PD1/PD-L1 and LAG3/MHC-II.
Methods: CB213 has been developed as a fully human PD1/LAG3 co-targeting multi-specific Humabody composed of linked V domains that avidly bind and block PD1 and LAG3 on dual-positive T cells.